Swiss Institute for Experimental Cancer Research, School of Life Sciences, EPFL, Lausanne
The CRISPR-Cas9 system is a bacterial adaptive immune system recently adjusted to serve as a powerful tool for genome-editing. Applying simultaneously the Cas9 endonuclease, a CRISPR-derived guiding RNA and a DNA repair template, it is possible to target and modify any genomic sequence by homologous recombination. On top of that, Cas9 fusion proteins can be used to activate or repress the expression of different genes of the human genome. Our laboratory currently applies CRISPR targeting and large-scale proteomics to identify genes playing a role in aging, cancer and telomere biology.
Host: Prof. Lluis Fajas
Mali et al. Science. 2013. Ran et al. Nature Protocols. 2013. Gilbert et al. Cell. 2013